Introduction to FOXO4-DRI 10mg (Proxofim)

FOXO4-DRI, also biochemically classified as Proxofim, is a synthetic, customized D-amino acid retro-inverso (DRI) peptide engineered to serve as a high-resolution molecular probe in senolytic research, cellular longevity tracking, and tissue regeneration trials. Designed to selectively target and eliminate dysfunctional senescent cells—frequently referred to as “killer cells” that resist natural clearance—FOXO4-DRI plays an imperative role in studying the biological mitigation of age-associated systemic decline.

Unlike standard L-amino acid proteins that are rapidly degraded by native proteolytic enzymes, the retro-inverso structural modification flips the peptide’s chiral centers and reverses its sequence direction. This configuration preserves the original side-chain topography needed to bind targets while providing exceptional resistance to enzymatic cleavage, substantially extending its experimental half-life. At USA PEPTIDE SCIENCES, we supply this advanced cellular rejuvenation matrix as a premium 10mg lyophilized vial, offering biochemistry, genetics, and molecular biology institutions an ultra-pure, standardized baseline reagent to map selective apoptotic pathways and tissue restoration kinetics.

Research Overview: Disruption of the p53-FOXO4 Interactome

The primary scientific value of FOXO4-DRI 10mg centers on its capability to disrupt a critical intracellular survival mechanism unique to senescent cells. As cells age or sustain irreversible genomic damage, they enter a state of permanent growth arrest while remaining metabolically active, secreting a harmful cocktail known as the Senescence-Associated Secretory Phenotype (SASP).

Key areas of active scientific investigation utilizing FOXO4-DRI 10mg include:

• Targeted Senescent Cell Apoptosis: Modeling the competitive inhibition of the forkhead box O4 (FOXO4) transcription factor. In senescent lines, endogenous FOXO4 actively binds to the p53 tumor suppressor protein, sequestering it within the nucleus and preventing it from triggering cell death. FOXO4-DRI mimics this binding interface, disrupting the p53-FOXO4 complex and allowing p53 to translocate to the mitochondria, where it initiates cell-autonomous apoptosis strictly within senescent populations.

• SASP Suppression and Microenvironmental Mapping: Investigating the subsequent reduction of localized inflammatory markers following senescent cell clearance. Researchers monitor downregulations in pro-inflammatory cytokines, chemokines, and matrix metalloproteinases (such as IL-6, TNF-$\alpha$, and MMPs) to evaluate how clearing senescent cells rejuvenates surrounding healthy tissues.

• Tissue Restoration and Stem Cell Niche Optimization: Analyzing the recovery of native tissue architecture in aged or damaged organ models. By removing senescent cells that actively poison local microenvironments, studies explore the reactivation of surrounding tissue-resident stem cells, observing improvements in muscle mass, skin density, renal function, and general physiological vitality.

• Retro-Inverso Pharmacokinetics and Stability: Evaluating the structural durability of the D-peptide sequence within complex biological mediums. Researchers use this formulation to contrast the sustained signaling curve of FOXO4-DRI against traditional, highly unstable L-peptides, establishing baseline models for advanced senolytic delivery systems.

Quality Standards & Analytical Testing

At USA PEPTIDE SCIENCES, laboratory data integrity and compound reproducibility are the fundamental core of our manufacturing operations. Every single production lot of FOXO4-DRI 10mg (Proxofim) undergoes a strict quality control validation protocol to eliminate compounding variables and experimental artifacts. We utilize High-Performance Liquid Chromatography (HPLC) coupled with Mass Spectrometry (MS) to confirm an absolute chemical purity profile of 99% or greater. This rigorous analytical validation verifies the exact D-amino acid sequence topography, precise molecular weight, and correct retro-inverso spatial conformation while ensuring the total absence of residual synthesis reagents, truncated fragments, heavy metals, or raw contaminants. A batch-specific Certificate of Analysis (COA) accompanies every order to guarantee absolute reproducibility.

Storage and Handling Requirements

To safeguard the complex retro-inverso bonds and prevent structural degradation of the lyophilized cake, all vials must be stored long-term in a freezer environment at -20°C. Prior to introducing the compound into your laboratory workflow, reconstitution must be carried out using an appropriate sterile, non-pyrogenic, or bacteriostatic diluent. Once transitioned into a liquid state, the peptide solution becomes highly sensitive to thermal breakdown; reconstituted vials must be maintained under constant refrigeration at 2°C to 8°C. Researchers must dissolve the compound via a slow, gentle swirling motion, avoiding any aggressive mechanical agitation, inversion, or shaking, which can disrupt the delicate synthetic matrix.

Research Use Disclaimer

The compounds distributed by USA PEPTIDE SCIENCES, including FOXO4-DRI 10mg (Proxofim) research vials, are designated strictly for laboratory research purposes only. Under no circumstances are these products approved or intended for human or veterinary consumption, direct clinical diagnostics, or therapeutic drug administration. All handling, measuring, and experimental evaluation must be conducted exclusively by qualified scientific professionals within a certified and monitored research facility.